|Year : 2022 | Volume
| Issue : 6 | Page : 1743-1753
Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma
Zafar Abbas1, Faisal Nouroz1, Samina Ejaz2
1 Department of Bioinformatics, Hazara University Mansehra, Mansehra, Pakistan
2 Department of Biochemistry, Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
|Date of Submission||09-May-2020|
|Date of Acceptance||28-Sep-2021|
|Date of Web Publication||16-Nov-2022|
Department of Biochemistry, Institute of Biochemistry, Biotechnology and Bioinformatics, The Islamia University of Bahawalpur, Bahawalpur
Source of Support: None, Conflict of Interest: None
Background: Cellular expression level of Breast Cancer-Associated Type 1 (BRCA1) encoded protein is the sign of genome integrity, stability, and surveillance. BRCA1 after sensing DNA damage activates repairing system and if mutated leaves genomic lesions unrepaired and triggers transformation of normal breast cells into cancerous ones.
Aims of study: We conducted in silico study to have a holistic view of BRCA1's correlation with multiple variables of breast invasive carcinoma.
Materials and Methods: We used user-friendly online GeneCardsSuite pathway-level enrichment analysis, UALCAN portal differential expression analysis, cBioPortal cancer genome platform for mutatome map construction, and cancer cell lines encyclopedia genomics of drug sensitivity toolkit to understand correlation of BRCA1 expression with the effectiveness of anti-cancer drugs.
Results: Contrary to general behavior of a tumor suppressor gene our study revealed BRCA1 overexpression under all circumstances. This novel finding needs to be explored further to understand functional impact of BRCA1 overexpression on the expression of many genes which are transcriptionally regulated by BRCA1 and promotion of tumriogenesis.
Conclusion: Our study highlights the potential role of BRCA1-regulated genes in oncogenesis and recommends use of BRCA1-linked genes as future therapeutic targets for effective disease management.
Keywords: Breast cancer-associated type 1, breast invasive ductal carcinoma, DNA damage repair pathways, Double strand brake, genome surveillance
|How to cite this article:|
Abbas Z, Nouroz F, Ejaz S. Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma. J Can Res Ther 2022;18:1743-53
| > Introduction|| |
The most prevalent cancer among women worldwide is the breast cancer which affects women of 154 countries and has the highest mortality rate in 103 countries. In 2018, more than 2 million females were diagnosed with breast carcinoma. Few genes such as breast cancer-associated Type 1 (BRCA1), BRCA2, PTEN, ATM, TP53, HRAS, and CHEK2 and the corresponding proteins are thought to be the significant genetic markers in familial breast carcinoma cases. The BRCA1/2 mutations are the major hallmarks of breast-related malignancies. It is estimated that the carriers of BRCA1 mutation carriers have more than 70% lifetime risk to develop breast cancer other than noncarriers., More than 75% of BRCA1 mutation carriers have a worse prognosis in basal-like (BL1) subtypes of breast cancer., BRCA1 performance during maintenance of genome's integrity depends on the deployment of associated protein complexes for repairing of double-strand breaks (DSB) in DNA. During DSB repairing process, recognition and initiation are mainly triggered through C-terminal domains of BRCA1 which mediates molecular associations with various proteins, including retinoblastoma protein 8, BTB domain, and CNC1 to constitute BRCA1 A complex. The BRCA1-BARD1 complex having E3 ubiquitin ligase activity carries out ubiquitination of a variant histone H2AX which in turn re-localizes TP53 at break sites., The BRCA1 associations with proteins such as MSH2, MSH6, MLH1, ATM, RAD50, MRE11, and NBS1 are necessary for RAD51 recruitment at DSB site. The protein complex containing RAD51 repairs DSBs by identifying homologous sequences., Breast tissue differentiation NOTCH/SLUG regulators have influential interactions with BRCA1. The NOTCH/SLUG regulators elevate the expression of JAG1 which binds with NOTCH receptor, and ultimately components of NOTCH pathway are up-regulated. Higher activity of NOTCH pathway is known to promote progression of cancer.,, While SLUG protein complex promotes metastasis by conferring stem cell-like features to the tumor cells. BRCA1 negatively regulates SLUG expression.
The multivariate interactions of BRCA1 with DNA damage repairing machinery consisting of various tumor suppressor proteins invite us to comprehensively analyze the status of BRCA1 mutations, expression, its promoter methylation pattern, and association with drug sensitivity profile of breast carcinoma tissues. The information obtained will be of clinical significance and can serve as a guide for therapeutic interventions for precision medicines.
| > Materials and Methods|| |
Various bioinformatics tools were employed during multi-step experimental strategy used during the study.
Breast cancer-associated type 1 characterization analysis
To characterize BRCA1 data were retrieved from GeneCardsSuite (www.genecards.org) which is a freely available online database containing information of HGNC approved genes (41,846), disease associated genes (13686), protein coding genes (21,137), pseudogenes (22,237), hot genes (500), gene clusters (14), genomic regions (3,780) of biological and clinical relevance, transcriptomics and proteomics data. We queried BRCA1 official gene symbols on homepage through “search box” and pressed “GO” option. The database offered valuable data regarding different aspects of BRCA1, including gene symbols, genomic view summery, protein domains, functions, pathway interactions, druggome information, genomic variants, and associated disorders. We explored information regarding participation of BRCA1 in the pathways which are activated in response to DNA damaging events.
Investigation of breast cancer-associated type 1 expression status
We investigated the status of BRCA1 gene expression in breast invasive carcinoma (BRIC) through UALCAN (www.ualcan.path.uab.edu), an online web portal consisting of The Cancer Genome Atlas (TCGA) ribonucleic acid (RNA)-seq level 3 data of 31 cancer types. The UALCAN portal enabled inquiring relative/differential expression status of BRCA1 across a wide range of normal and cancerous samples in association with multiple parameters including gender, race, age groups, and numerous other pathological features and stage of disease (in case of patients). The information was retrieved in the form of expression data graphs and box plots. We pressed “Analysis” option available on homepage that ultimately opened “Search box” for gene scanning in relevant cancer dataset. We entered BRCA1 gene in “Box,” selected “Beast Invasive Carcinoma” dataset and pressed “Explore” tab which offered whisker box plot representation of differential expression. UALCAN utilized interquartile ranges including minimum, medium, and maximum values. The transcript per million values above/below upper quartile were designated as high and low/medium expression, respectively.
Breast cancer-associated type 1 protein expression analysis in breast cancer
We analyzed BRCA1 protein expression for determining correlation among transcriptomics to proteomics level of gene expression in various breast malignancy-related aspects, including stages, race, age-groups, and cancer subclasses. The UALCAN (www.ualcan.path.uab.edu) online web portal integrates BRCA1 protein expression data from CPTAC consortium and allows retrieval and analysis of protein expression data across the samples of diverse attributes. The web portal presented BRCA1 protein expression data in the form of box plots.
Determination of methylation status of breast cancer-associated type 1 promoter
We analyzed BRCA1 promoter to have an account of its methylation status using UALCAN (www.ualcan.path.uab.edu) an online web portal that allows us to correlate gene expression ratio with DNA methylation rank. UALCAN processes DNA methylation level through beta values from 0 (unmethylated) to 1 (fully methylated) with cut-off values 0.7–0.5 (hyper-methylation) and 0.3–0.2 (hypo-methylation).
Breast cancer-associated type 1 mutatome map mining
We explored BRCA1 mutatome map from cBioPortal for Cancer Genomics (www.cbioportal.org), an online database, by querying BRCA1 gene symbol with the selection of “BRIC TCGA, Cell 2015” and pressed “Submit” query option. The portal presented “Mutation” tab provided graphical summery and table of all BRCA1 gene attributes, i.e., nonsynonymous mutations, positions and frequency in BRIC samples. Moreover, the cBioPortal revealed comprehensive information regarding BRCA1 genomic lesions including missense, nonsense, nonstart, and frameshift insertions/deletions.
Correlational analysis of breast cancer-associated type 1 expression and drug resistance
We investigated relationship of BRCA1 expression status with the response of tumor to anti-cancer drugs used for breast cancer treatment. The information was obtained through cancer cell lines encyclopedia and the genomics of drug sensitivity (CCLE GDSC) gene expression-drug sensitivity correlations toolkit (www.public.tableau.com/CCLE_GDSC_Correlations). We selected BRCA1 gene from CCLE GDSC “gene list” and adjusted “EC50/IC50” coefficient concentrations. The CCLE GDSC toolkit revealed green (negative nonresistant) or red (positive resistant) colored representations. Data were tabulated to reflect the association of BRCA1 expression with drug effectiveness.
Association of breast cancer-associated type 1 expression and survival of patients
The impact of BRCA1 expression on survival of patients was accessed through information available on UALCAN (www.ualcan.path.uab.edu), an online web portal, in the form of Kaplan–Meier (KM) survival plot. The web portal provided KM plots to indicate the relation of BRCA1 expression with three parameters, i.e., time from days of diagnosis to death or days to last fellow-up, status of alive or dead, and finally expression of high, medium, and low. The KM survival curves of high, medium, and low expression were compared through log-rank test analysis.
| > Results|| |
Breast cancer-associated type 1 enrichment analysis
The information extracted through GeneCardsSuite v4.12 revealed BRCA1 as a nuclear 1863 amino acid containing phosphoprotein encoded by a gene located on chromosome 17q21.31 (125,951 bases from 43,044,295 to 43,170,245) which participates in maintenance of genome stability and prevention of tumriogenesis. The BRCA1 protein forms complex with RNA Polymerase II, and histone deacetylases using its BRACT domain and mediates transcription of a set of genes. Among the BRCA1-regulated genes, many participate in the homologous recombination-based repair mechanism of double-strand brakes. The maintenance of genome integrity is a vital phenomenon to ensure survival and development of eukaryotic multicellular organisms. The base modifications, interstrand cross-links, and strand breaks are characterized as DNA damages. The natural cellular signaling system senses and responds to any DNA damage based upon the location, chemical nature, cell cycle timing, and type of damage events. BRCA1 induces BRCA1-associated genome surveillance complex consisting of multiple proteins such as MSH2, MSH6, MLH1, ATM, BLM, and RAD50-MRE11-NBS1 protein complexes for the detection and repairing of DNA lesions. In response to any DNA damage BRCA1 and RAD51 co-localize to subnuclear region by FANCD2 ubiquitylation due to the activation of nuclear complex comprised of proteins such as FANCA, FANCC, FANCE, FANCF, and FANCG. The homologous recombination repairing process is initiated and progresses through BRCA1, BRCA2, RAD51, and FANCD2 in DNA repairing mechanism. The nuclear phosphoprotein BRCA1 establishes interactions with RAD50-RAD51-MRE11-NBS1 complex. The CHK2 phosphorylation is triggered through ATM/ATR activation which further phosphorylates BRCA1. The phosphorylated BRCA1 influences extent of ubiquitin ligation by associating with BARD1 to ensure the role of BRCA1 in the maintenance of genome stability. The BRCA1 is known to activate GADD45 which has a significant role in DNA damage repairing via regulating G2/M and G1/S checkpoints through CHK1/PLK1 complex. BRCA1-STAT1 complex inhibits growth by activating RB and IFN-gamma genes. The chromatin remodeling and homologous recombination repair process are initiated through BRCA1-BACH1-SWI/SNF complex that regulates HDACs.,, Information regarding BRCA1 interaction profile is summarized in [Figure 1].
|Figure 1: Breast cancer associated type 1 DNA damage repairing pathway (Figure is retrieved from genecards database)|
Click here to view
Breast cancer-associated type 1 differential expression analysis
Breast cancer has various types under TNM staging system based on tumor size (T), tumor-lymph node interaction (N), and tumor-derived metastasis (M). When breast carcinoma is diagnosed at higher stages, it reduces survival chances, and lowered stages are closer to normal cellular physiology with less aggressive tumorigenic signatures. Stage 1–3 are invasive in nature, but existing cancerous cells remain confined within in the breast tissue but in Stage 4 tumor cells spread into regional lymph nodes and distant body organs with worse prognosis. Our results showed that BRCA1 is significantly overexpressed (P < 0.005) in Stage 1 (10.55), Stage 2 (11.8), Stage 3 (10.48), and Stage 4 (8.65) of the disease as compared to the normal expression (4.95). Moreover, Stage 1 also differed significantly (P < 0.005) than Stage 2 and Stage 3 [Figure 2]. Breast cancer showed interesting prevalence record in less or more-developed populations with high incidence rates in European and African countries. BRCA1 was observed to have a higher expression (P < 0.005) in Caucasian (10.86), African-American (11.23), and Asian (11.36) races as compared to the normal expression (4.95). Breast cancer reported in above 50-year-old females is mostly aggressive due to several factors, including abnormal menopause setup, poorer medical conditions, and late diagnosis. BRCA1 has shown up-regulation (P < 0.005) in 21–40 years (10.69), 41–60 years (11.06), 61–80 years (11.44), and 81–100 years (9.79) as compared to normal expression (4.95). While the difference between patients of various population- and age-based groups was found insignificant (P > 0.005). Majority of the published breast cancer-related work revolves around females rather than males due to rare chances of this disease in males. However, BRCA1 is known to have higher expression (P < 0.005) level in both male (27.31) and female (11.16) patients as compared to the expression level documented in healthy cancer-free cells (4.95). Moreover, BRCA1 expression level documented in male patients differed significantly (P < 0.005) than females. BRCA1 expression in association with different factors is shown in [Figure 2].
|Figure 2: Association of breast cancer associated type 1 expression with various stages of disease, and race, gender and age of breast cancer patients. The number of samples in a particular dataset is indicated by n. Statistical analysis revealed significant variations (P < 0.005) among following comparisons: Normal-versus-Stage1, Normal-versus-Stage2, Normal-versus-Stage3, Normal-versus-Stage4, Stage1-versus-Stage2, Stage1-versus-Stage3, normal-versus-caucasian, normal-versus-African American, normal-versus-Asian, normal-versus-male, normal-versus-female, male-versus-female, normal-versus-age (21–40 years), normal-versus-age (41–60 Years), normal-versus-age (61–80 Years) and normal-versus-age (81–100 years). However, variations among various patients groups (based upon individual cancer stages and patient's race) and patients-versus-normal group were found to be insignificant (P > 0.05). Detail of statistical significance level is given in supplementary data|
Click here to view
Breast cancer is categorized into luminal, human epidermal growth factor receptor 2 (HER2)+ and triple-negative breast cancer (TNBC) based on the expression status of cellular estrogen receptors, progesterone receptors, and HER2. In TNBC, the expression all three receptors is lost but prolactin and androgen receptors are expressed frequently. BRCA1 was examined to have higher expression (P < 0.005) in Luminal (10.46), HER2+ (8.16), and TNBC (13.68) as compared to the one observed in normal cellular expression (4.95). Breast cancer has a diverse association with menstrual cycle and considerably varies from Pre-Peri-Postmenopausal situations due to production of estrogen. BRCA1 was examined to have overexpression (P < 0.005) in premenopause (10.51), peri-menopause (13.53), and postmenopause (11.21) with reference to normal expression (4.95). Breast cancer is histologically categorized mainly into three types, i.e., invasive ductal carcinoma (IDC) cancer of milk transporting duct, and invasive lobular carcinoma (ILC). The cancer of milk-producing glands and metaplastic type of carcinoma spreads into distant parts of body. IDC has various types such as mucinous, medullary, and papillary which have specified morphological features. However, few not otherwise specified forms of IDC also exists which are termed as INOS. BRCA1 was documented to have up-regulation (P < 0.005) in IDC (12.04), ILC (9.36), Mucinous (8.94), Medullary, Mixed (11.27), and others (10.12) as compared with normal expression (4.95). The metaplastic (8.73) group had significantly higher expression of BRCA1 than IDC and other types. Moreover, IDC exhibited higher expression (P < 0.0005) than ILC. TNBC has various forms based on genomic mutations which are BL1, BL2, immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptors (LAR). The analysis showed significant overexpression (P < 0.005) of BRCA1 in BL1 (22.54), BL2 (9.37), IM (11.75), M (14.19), MSL (7.33), and LAR (6.54) as compared to normal expression (4.95). Information is summarized in [Figure 3].
|Figure 3: Status of breast cancer associated type 1 expression in different subclasses, triple negative breast cancer, Menopause states and histological forms of breast cancer. The number of samples in a particular dataset is indicated by n. Statistical analysis revealed significant variations (P < 0.05) among following comparisons: Normal-versus-luminal, normal-versus-human epidermal growth factor receptor 2 positive, normal-versus-triple negative breast cancer, normal-versus-triple negative breast cancer- basal-like 1, normal-versus- triple negative breast cancer-Immunomodulatory, normal-versus-triple negative breast cancer-Mesenchymal, normal-versus- triple negative breast cancer-universitas sebelas maret, luminal-versus-triple negative breast cancer-mesenchymal stem-like, triple negative breast cancer- basal-like 1-versus-triple negative breast cancer- basal-like 2, triple negative breast cancer- basal-like 1-versus-triple negative breast cancer-mesenchymal stem-like, normal-versus-premenopause, normal-versus-peri-menopause, normal-versus-postmenopause, normal-versus-invasive ductal carcinoma, normal-versus-invasive lobular carcinoma, normal-versus-mixed, normal-versus-Other, normal-versus-mucinous, normal-versus-medullary, invasive ductal carcinoma-versus-invasive lobular carcinoma, invasive ductal carcinoma-versus-metaplastic and other-versus-metaplastic. However, variations among various patients groups (based upon breast cancer subclasses, major subclasses (with triple negative breast cancer types), menopause Status and histologic subtypes) and patients-versus-normal group were found to be insignificant (P > 0.05). Detail of statistical significance level is given in supplementary data|
Click here to view
Breast cancer-associated type 1 protein expression analysis
The BRCA1 protein expression was higher in Stage II (2.03 Z-value), Stage III (1.62 Z-value), Caucasian (2.02 Z-value), Asian (2.01 Z-value), African-American (1.79 Z-value), 41-60 (2.03 Z-value), 21–40 (1.79 Z-value), 61–80 (1.52 Z-value), Luminal (2.02 Z-value), and TNBC (1.86 Z-value) than Stage I (0.37 Z-value), 81–100 (0.66 Z-value), and HER2+ (0.03 Z-value). Information has been summarized in [Figure 4].
|Figure 4: Breast cancer associated type 1 protein expression analysis in breast cancer stages, race, age-groups and cancer subtypes. All variations were statistically insignificant (P > 0.05) except caucasian-versus-Asian|
Click here to view
Methylation status of breast cancer-associated type 1 promoter
DNA methylation involves the addition of methyl group to CpG islands present in promoter or other regions of any gene. The promoter methylation promotes transcriptional silencing and it is the most prevalent gene silencing mechanism, specifically in cases of tumor suppressor genes. In cancer, usually, cell proliferation-associated genes are hypomethylation while DNA repairing genes are hypermethylated. In our study, BRCA1 appeared to have very lower degree of hyper-methylation in majority of the samples and normal subjects as indicated by the lower beta value (i.e., ranging from 0.33 to 0.35). Statistical analysis was carried out to compare normal subjects' methylation status (0.36) with the patients. Results revealed significant variations (P < 0.005) in Stage 1 (0.35), Stage 2 (0.35), Stage 3 (0.35), Caucasian (0.35), African-American (0.34), Asian (0.35), female (0.35), 41–60 years (0.35) and 61–80 years (0.35). Data are summarized in the form of box and whisker plot [Figure 5].
|Figure 5: Breast cancer associated type 1 promoter methylation status in in breast cancer patients of different stages, gender, race and age. The number of samples in a particular dataset is indicated by n. Beta value is used to reflect the extent of DNA methylation and it ranged from 0 (unmethylated) to 1 (fully methylated). The lower cut-off value (0.3–0.25) indicates hypo-methylation while hyper-methylation is considered to have higher beta value (0.7 – 0.5) as per defined criteria. The number of samples in a particular dataset is indicated by n. Statistical analysis revealed significant variations (P < 0.005) among following comparisons: Normal-versus-Stage1, normal-versus-Stage2, normal-versus-Stage3, normal-versus-caucasian, normal-versus-African American, normal-versus-Asian, normal-versus-female, normal-versus-age (41–60 Years) and normal-versus-age (61–80 Years). However, variations among methylation status of various patients groups and patients-versus-normal group were found to be insignificant (P > 0.05). Detail of statistical significance level is given in supplementary data|
Click here to view
Extraction of breast cancer-associated type 1 mutatome map
We determined BRCA1 differential expression in BRIC-TCGA Cell 2015 dataset of 816 samples in which 40 samples (4.9%) showed altered expression. While 16 samples had missense mutation unknown significance and 1 sample was observed to have inframe mutation of unknown significance. Overall, BRCA1 showed 2.0% amplification, 0.9% homozygous deletion, and 2.2% mutation in BRIC dataset [Figure 6].
|Figure 6: Mutational spectrum of breast cancer associated type 1 in breast invasive carcinoma|
Click here to view
BRCA1 has 5 significant domains, i.e., zf_C3HC4 zinger finger type (Ring finger 24–64 AA), serine-rich domain associated with BRCT (344–507 AA), ethylene insensative 3 (EIN3 648–978 AA), and BRCA1 C Terminus domain (1662-1723/1757-1842 AA). In the present study, among 1863 amino acids of BRCA1 18 BRIC-associated mutations were detected through in silico analysis. The detected mutations included 12 missense mutations documented in IDC of breast, i.e., G1788V, Q1811 L, P1238H, D1344H, E9Q, K50T, S1027I, D366N, D96H, D2E, S915C, and P1126Q. While 5 truncating mutations were recorded in IDC (X1559_Splice, E720 and P1614Qfs19) and mixed both invasive ductal/lobular carcinoma cases (Q934 and T688Vfs12). A single in-frame mutation C644del has been noticed in IDC [Figure 7].
|Figure 7: Breast cancer associated type 1 mutatome map in breast invasive carcinoma|
Click here to view
Correlation of breast cancer-associated type 1 and drug sensitivity profile of breast invasive carcinoma
BRCA1 expression enhances the effectiveness of many drugs which either inhibit tumor growth preventing (Obatoclax Mesylate), cancer cells migration (AG-014699/Rucaparib), and tumor angiogenesis (BX-912) or act as antineoplastic agent (BMS-754807), apoptosis inducer (CAL-101 or Idelalisib), cell growth regulatory BRAF inhibitor (Debrafenib), hedgehog signaling mediated oncogenes suppressor (GDC0449 or Vismodegib), antitumor metabolic activist (GSK1070916), angiogenesis-based metastatic inhibitor (KIN001-236), growth-mediated signaling transduction pathway inhibitor (LFM-A13), S-phase inhibitor (MLN4924 or Pevonedistat), cell cycle regulation inhibitor (NPK76-II-72-1), cellular adhesion inhibitor (PF-562271), anti-proliferatory agent (Ruxolitinib), stress response inducer (Salubrinal), tumor cell growth inhibitor (SNX-2112), and anti-metastatic (XMD14-99). Information regarding drug sensitivity profile is summarized in [Table 1].
|Table 1: Breast cancer associated type 1 association with drug sensitivity status of breast invasive carcinoma|
Click here to view
Association of breast cancer-associated type 1 expression and survival of patients
There is no effect of BRCA1 expression level on the survival of BRCA patients as it is reflected by the KM survival curve analysis [Figure 7]. About 70% of the BRCA patients having high and low/medium expression level exhibited the same survival pattern. While 25% of the patients having higher expression of BRCA1 had slightly higher survival rate than patients having low/medium expression level, but the difference is statistically insignificant (P = 0.15). The same was true for the effect of BRCA1 expression in combination with race (P = 0.57), gender (P = 0.15) and cancer type (P = 0.089) on the survival of BRCA patients [Figure 8].
|Figure 8: Kaplan–Meier plots to reflect the association of breast cancer associated type 1 expression status alone and in correlation with race, gender and cancer type on survival of breast cancer associated type 1 patients. Statistical analysis revealed that all variations were insignificant|
Click here to view
| > Discussion|| |
Among women, the prevalence ratio of breast-related malignancy is 30% of the total known cancer reports. While TNBC accounts for 12%–17% of the breast carcinoma cases., BRCA1 is a shuttle protein that is translocated from cytoplasam to nucleus as part of TP53 signaling pathway in response to the DNA damage., The 1863 amino acids encoding BRCA1 gene is positioned at chromosome 17q21 and consists of 24 exons. The BRCA1 protein is composed of many functional domains, including RING finger N-terminal domain, BRCT domains, coiled-coiled domain, SQ cluster, and two nuclear localization signals. BRCA1 mutations are associated with both heritable and sporadic types of breast cancer. Various studies have reported the role of BRCA1 mutations in breast, prostate, peritoneal, ovarian, fallopian tube, and pancreatic cancers in either women or men. Multiple evidences are available regarding numerous mutations in RING finger and BRCT domains. Both domains mediate influential protein-protein interactions essential for nucleotide repairing processes.,,,,,,,,, Initial studies mentioned significance of BRCA1 in tumorigenesis, hyperplasia, and abnormal ductal development. Several high-grade carcinomas exhibit loss of BRCA1 function or lowest level of expression with higher proliferation speed.,,, BRCA1 is influential member of BRCAness phenomenon and undergoes mutations, copy number alterations, aberrant expression, and promoter methylation. The dysfunctional BRCA1 is the indictor of less effective nucleotide repairing mechanism which ultimately leads to the generation of genomic lesions. The impact of BRCA1 gene expression on diverse breast cancer-associated attributes, i.e., TNBC subtypes, stages, age-groups, race, menopause status, and histological forms has not been extensively investigated [Figure 4].
Due to the lack of confirmed drug targets in TNBC, it behaves clinically aggressively that leads to worse or poor prognosis as compared with other molecular subtypes of breast cancer. It is known that chance of TNBC patients to have mutated BRCA1 is 75% higher than patients of other molecular subtypes., In our study, all molecular subtypes of TNBC have elevated BRCA1 expression which shows a worse prognosis with lethal invasive nature of proliferation due to diverse set of molecular alterations. Several studies reported worse prognosis in TNBC patients having BRCA1 mutations in their genome compared with BRCA1 nonmutated carriers.,,,,, Here, the availability of normal BRCA1 protein could protect the error-prone genomic lesions which may ultimately lead to the activation of oncogenes. These in silico findings invite researchers to conduct more rational experimental studies to elucidate the impact of BRCA1 expression in TNBC patients.
In our study, BRIC datasets showed BRCA1 overexpression in all BRIC-associated variables including stage of disease, race, age, gender, menopause status, molecular subtypes, histological subtypes, and TNBC types. Higher BRCA1 expression observed in Stage 2 than Stage 1 and Stage 3 reflects insignificant impact of BRCA1 elevated expression on initiation step of breast tissues transformation. In Stage 1–3, breast tumor cells are ready to invade nearby lymph node tissues by replicating supportive genomic alterations. The status of BRCA1 expression is more dysregulated in the Asian race comparative to African, American, and Caucasian populations. From 41 to 81-year-old age, cases showed elevated expression of BRCA1 than younger patients. This finding indicates regulatory impact of BRCA1 in age-based carcinoma and suggests its role as invasive carcinoma marker in old age patients. Our study validates previous reports regarding higher breast cancer prevalence in old-aged patients and has been linked with the lack of awareness and delayed diagnosis among the Asian community.,,, BRCA1 deregulation in Asian race with elder ages confirmed. Low prevalence male BRIC patients have been shown to exhibit higher expression of BRCA1 that attracts researchers to investigate the factors responsible for cancer progression in male breast carcinomas. During pre- and postmenopausal conditions of BRIC, patients BRCA1 overexpression indicates its associations with multi-faceted hormonal pathways. In breast malignancy, pre-postmenopausal status is very crucial factor that plays a role in receptor-mediated carcinogenesis triggered by altered regulation of estrogen and follicular stimulating hormone.,, In breast ductal carcinoma (medullary form), patients BRCA1 overexpression highlights its clinical significance. In all TNBC types, elevated BRCA1 expression, specifically BL1/M/IM suggests its contribution in stem cell-like behavior.
In our study, the BRCA1 promoter methylation status insignificantly varied than normal subjects. However, previous studies have reported hypermethylation and silencing of BRCA1 promoters in breast cancer patients.
BRCA1 mutatome map showed significant mutations in BRIC dataset. Majority of the missense mutations observed in IDC are localized in a variety of domains, including BRCT domain, SQ cluster, RING finger motif, and nonhomologous end-joining region. These missense mutations make BRCA1 protein nonfunctional in the context of protein binding sites for phosphorylation and ubiquitination which are essential for normal repairing processes. IDC patients 3 truncating mutations were detected in BRCT, a coiled-coil region, and RING finger domains. These domains are essential for DSBs repairing process. There is a single inframe mutation in homologous recombination RAD50/RAD51 binding region which is important for nuclear localization, DNA binding, and transcriptional regulation. Our results revealed that BRCA1 enhances effectiveness of many therapeutic anti-cancer drugs. Our findings validate BRCA1 interaction with moesin/radixin/ezrin drugs, reduced motility, and number of malignant cells. We further observed that variations in the BRCA1 expression level have no influence on the survival rate of BRCA patients.
Our study raises several serious concerns regarding BRCA1 overexpression in breast cancer. BRCA1 is a tumor suppressor that performs key role in repairing DSBs, but why it is overexpressed in carcinoma? Which molecular factors are responsible for its upregulation in tumorigenic conditions? Why promoter methylation mediating pathways are deactivated in BRIC patients? Why BRCA1 overexpression is not sufficient to repair genomic lesions? Which are the molecular determents that manipulate BRCA1 overexpression to promote tumriogenesis? What is the role of endocrinological factors to determine BRCA1 fate under diverse molecular microenvironment? How BRCA1 mutations dysregulate expression rate or lead to a nonfunctional protein?
| > Conclusion|| |
BRCA1 is an essential factor which is known to regulate normal development and physiology of breast tissues. While its aberrant expression promotes breast cancer progression due to lack of genome surveillance machinery continuously recognizing and fixing the damages. Researchers have previously suggested that tumor biology can be better understood by focusing on the role of BRCA1 in maintaining genome integrity and mediating normal cell cycle. Our study proposes that BRCA1 upregulation may facilitate tumor progression and demands extensive molecular analysis of regulatory factors to understand role of BRCA1 in carcinogenesis. This in silico study provided enough data which after experimental validation can be employed in future to develop versatile therapeutic strategies based on BRCA1-mediated oncogenesis.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| > References|| |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999;1:14-7.
Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-36.
Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, et al.
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-micro vascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5.
Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000;18:287-95.
Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 2011;12:68-78.
Ohta T, Sato K, Wu W. The BRCA1 ubiquitin ligase and homologous recombination repair. FEBS Lett 2011;585:2836-44.
Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-63.
Savage KI, Harkin DP. BRCA1, a 'complex' protein involved in the maintenance of genomic stability. FEBS J 2015;282:630-46.
Densham RM, Morris JR. The BRCA1 Ubiquitin ligase function sets a new trend for remodelling in DNA repair. Nucleus 2017;8:116-25.
Romero A, García-García F, López-Perolio I, Ruiz de Garibay G, García-Sáenz JA, Garre P, et al.
BRCA1 alternative splicing landscape in breast tissue samples. BMC Cancer 2015;15:219.
Buckley NE, Nic An tSaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, et al.
BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. Nucleic Acids Res 2013;41:8601-14.
Lindeman GJ, Visvader JE. Cell fate takes a slug in BRCA1-associated breast cancer. Breast Cancer Res 2011;13:306.
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al.
Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22.
van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr) 2011;34:71-88.
Guttmacher AE, Collins FS. Genomic medicine – A primer. N Engl J Med 2002;347:1512-20.
Chan IS, Ginsburg GS. Personalized medicine: Progress and promise. Annu Rev Genomics Hum Genet 2011;12:217-44.
Verma M. Personalized medicine and cancer. J Perinat Med 2012;2:1-14.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al
. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
Peter S, Lakhani SR. Recent developments in the molecular pathology of breast cancer. Breast Cancer 2009;98:23-7.
Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma-rare types: Review of the literature. Ann Oncol 2009;20:1763-70.
Correa Geyer F, Reis-Filho JS. Microarray-based gene expression profiling as a clinical tool for breast cancer management: Are we there yet? Int J Surg Pathol 2009;17:285-302.
Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019;321:288-300.
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al.
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-9.
Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin Cancer Biol 2018;51:22-35.
El Helou R, Wicinski J, Guille A, Adélas239;de J, Finetti P, Bertucci F, et al.
Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. Stem Cells 2014;32:3031-6.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
Rodríguez JA, Henderson BR. Identification of a functional nuclear export sequence in BRCA1. J Biol Chem 2000;275:38589-96.
Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: Where do we go from here? Eur J Hum Genet 2016;24 Suppl 1:S3-9.
Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, et al.
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-7.
Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, et al.
Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 2004;64:5013-9.
Coupier I, Baldeyron C, Rousseau A, Mosseri V, Pages-Berhouet S, Caux-Moncoutier V, et al.
Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations. Oncogene 2004;23:914-9.
Davis AJ, Chi L, So S, Lee KJ, Mori E, Fattah K, et al.
BRCA1 modulates the autophosphorylation status of DNA-PKcs in S phase of the cell cycle. Nucleic Acids Res 2014;42:11487-501.
Lin WY, Wilson JH, Lin Y. Repair of chromosomal double-strand breaks by precise ligation in human cells. DNA Repair (Amst) 2013;12:480-7.
Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 2013;23:693-704.
Dohrn L, Salles D, Siehler SY, Kaufmann J, Wiesmüller L. BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1. Biochem J 2012;441:919-26.
Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010;11:138-48.
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015;313:1347-61.
Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, et al.
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999;22:37-43.
Taylor J, Lymboura M, Pace PE, A'hern RP, Desai AJ, Shousha S, et al.
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 1998;79:334-42.
Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, et al.
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999;21:236-40.
Jarvis EM, Kirk JA, Clarke CL. Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 1998;101:109-15.
Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, et al.
p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 2011;71:5546-57.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90.
Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, et al.
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat 2012;136:795-804.
Wu L, Wang F, Xu R, Zhang S, Peng X, Feng Y, et al.
Promoter methylation of BRCA1 in the prognosis of breast cancer: A meta-analysis. Breast Cancer Res Treat 2013;142:619-27.
Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al.
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Ann Oncol 2015;26:523-8.
Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, et al.
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Res Treat 2016;157:157-65.
Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, et al.
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011;130:145-53.
Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, et al.
BRCA1 promoter methylation is a marker of better response to anthracyclinebased therapy in sporadic TNBC. Breast Cancer Res Treat 2013;141:205-12.
Boukerroucha M, Josse C, ElGuendi S, Boujemla B, Frères P, Marée R, et al.
Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer 2015;15:755.
Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 2000;249:35-54.
Shawarby M, Al-Tamimi D, Ahmed A. Molecular classification of breast cancer: An overview with emphasis on ethnic variations and future perspectives. Saudi J Med Med Sci 2013;1:14-9. [Full text]
Mehdi I, Abdulmasood AA, Bahrani BJ. Breast cancer molecular subtypes in Omani patients: Correlation with age, histology, stage distribution, and outcome – An anaylsis of 542 cases. J Clin Oncol 2011;29 27 Suppl: 219.
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al.
Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.
Friedenreich CM, Cust AE. Physical activity and breast cancer risk: Impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 2008;42:636-47.
Talamini R, Franceschi S, La Vecchia C, Negri E, Borsa L, Montella M, et al.
The role of reproductive and menstrual factors in cancer of the breast before and after menopause. Eur J Cancer 1996;32A: 303-10.
Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, et al.
Stages of reproductive aging workshop (STRAW). J Womens Health Gend Based Med 2001;10:843-8.
Gao Y, Jones A, Fasching PA, Ruebner M, Beckmann MW, Widschwendter M, et al.
The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clin Epigenetics 2015;7:126.
Apostolou P, Fostira F. Hereditary breast cancer: The era of new susceptibility genes. Biomed Res Int 2013;2013:747318.
Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M, et al
. A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 2011;192:497-512.
Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene 2006;25:5906-11.
Ginestier C, Liu S, Wicha MS. Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell 2009;5:229-30.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]